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INTRODUCTION
Tumor cells are often found in the peripheral blood 
of cancer patients, even those with localised cancer 
or who have had a primary tumor removed. Such cells 
are called circulating tumor cells (CTC) and may derive 
either from the primary tumor or from a metastasis. 
Presence of CTC in blood has been shown to correlate 
with metastasis, poor prognosis and poor treatment 
response and is considered important for the meta-
static process. CTCs are thus a promising target for 
early diagnosis and characterisation of metastatic 
cancer, as well as for planning treatment and following 
patient response. Since CTCs may be heterogeneous 
and as rare as one cell per 105–107 mononuclear cells, 
enrichment and detection presents a challenge [1]. 
The aim of this report is to discuss a strategy for find-
ing CTC-specific antigens that may be used for ac-
curate CTC enrichment and detection.
What kills cancer patients is usually metastasis. 
Often, clinical signs appear only when the tumor has 
been existing for years or even decades and may 
already be widely metastasised throughout the body. 
In such cases, treatment may be inefficient with risk 
of resistance development, since the continuous long-
term genetic selection, together with the metastatic 
process, may create highly aggressive, genetically 
unstable and different phenotypes. The first steps 
in metastasis involve tumor cells detaching from their 
tissue of origin and travelling through the bloodstream 
to metastatic niches in other organs, where they may 
lay dormant for decades as micro-metastases until 
symptoms appear [2]. It is necessary to diagnose 
cancer as early as possible in the metastatic process, 
and detection of CTCs offers a way of detecting metas-
tasis long before the end of dormancy and presence 
of symptoms.
Several different techniques for enrichment and 
detection of CTCs exist, based on differences between 
cancer cells and leukocytes in gene expression, anti-
gen expression or physical characteristics. 
Measuring expression of tumor specific genes 
or mutations in peripheral blood cells by qPCR may 
be used as a proxy for CTC detection. However, 
this approach alone still requires enrichment before 
analysis. Also, it requires cell lysis, making further 
CTC enumeration, characterisation and culturing 
impossible [1].
Antigen-based methods rely on a few markers that 
have long been known to be overexpressed in cancer. 
The cells may be captured with antibodies or aptamers 
toward the markers, or labelled for subsequent cytom-
etry analysis. Common CTC markers are cytokeratins 
(CK) and epithelial cell adhesion molecule (EpCAM). 
Antigen-based methods may be used for enrichment, 
detection and enumeration of CTCs, and do not re-
quire cell lysis. The problems with these approaches 
are related to the markers. CK may be expressed 
in leukocytes, while EpCAM is not expressed at all 
in a range of cancers, such as sarcomas, and loss 
of EpCAM is a component in epithelial-mesenchymal 
transistion (EMT), a step in metastatic progression. 
This may lead to false negative CTC detection results 
in progressed cancer [1]. 
Physical methods are based on a continuously 
distributed physical cell characteristic, such as size, 
hardness, optical or acoustic characteristics. These 
characteristics affect particle flow and may be used 
for cell separation. As of now, there have been few 
trials of such methods for actual CTC detection and 
counting. Because of CTC heterogeneity, and the fact 
that the continuous distribution will always lead to com-
promises between purity and yield, they are probably 
best suited for enrichment followed by antigen-based 
detection [3].
Thus, to address CTC heterogeneity and allow si-
multaneous enrichment and detection of viable cells, 
reliable cell surface markers of CTCs are needed. 
These markers may be used both to enrich blood sam-
ples for CTCs and to detect CTCs enriched by other 
methods. The aim of this report is to discuss an unbi-
ased strategy to obtain such markers.
PROTOCOL
If a CTC detection system is based on use of cul-
tured cells, this system may not hold in clinical applica-
tions, as differences exist between cultured cells and 
patient cells. For example, sorting CD45+EpCAM- 
cells by FACS detected CTCs in vitro but not in vivo 
[4]. Thus, clinical samples are necessary to obtain 
reliable CTC surface markers. The first step is therefore 
to collect blood from a number of patients represent-
ing healthy controls, as well as a number of different 
cancers of both epithelial and stromal origin.
After centrifugation, RBC lysis and immunomag-
netic CD45 depletion, a method successfully used 
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to enrich non-EpCAM CTCs in an unbiased way [5], 
only non-blood cells will remain. The cells will be ex-
posed to a biotinylation reagent, adding a covalently 
linked biotin tag to all surface proteins. After lysis, bi-
otin-bound proteins will be captured on avidin-coated 
resins. After cleavage of a biotin linker, for example 
by disulfide bridge reduction, proteins are eluted. This 
method has been shown to enrich surface membrane 
proteins specifically and with high purity [6]. Enriched 
proteins will thus represent the membrane-bound 
fraction, and will be subject to digestion into short 
peptides, followed by mass spectrometry. The same 
process will be performed on the CD45-depleted WBC 
fraction. Thus, four groups will be analysed by MS for 
every cancer type; healthy non-WBC, cancer non-WBC 
and the CD45+ leukocyte fractions from both groups.
1. Polypeptide fragmentation

2. Chromatographic separation

3. Mass spectrometry 1

4. Peptide fragmentation

5. Mass spectrometry 2

6. Spectral counting
Fig. 1. LC-MS/MS shotgun proteomics. 1. Proteins are digested 
into shorter peptides, for example with trypsin and CNBr. 2. 
Peptides are separated through multiple chromatographic 
steps. In the Mudpit approach, strong cation exchange and 
reverse-phase chromatography separate peptides by charge 
and hydrophobicity. 3. Peptides eluted from chromatography 
column are ionised by ESI and enter the mass spectrometer, 
where mass to charge ratios (m/z) of the peptides are measured, 
giving peptide masses. 4. The peptides are further fragmented 
in the mass spectrometer. A number of different fragmentation 
methods exist, such as collision-induced dissociation. 5. Peptide 
fragment m/z are measured, giving sequence information for 
the fragmented peptide. 6. Numbers of fragmentation spectra 
representing the same peptide are compared between groups, 
giving relative quantification of peptide amounts between the 
groups (Pictures from Wikimedia Commons).
Study of membrane proteins is difficult because 
the hydrophobic transmembrane domains make pro-
teins difficult to separate, transmembrane peptides 
are difficult to solubilise and these peptides have few 
sites for tryptic digestion. The separation problem can 
be somewhat alleviated in 2D approaches by using 
for example 16-BAC or blue-native PAGE separation 
in the first dimension, and in LC approaches by using 
multi-dimension separations, such as Mudpit. Solubil-
ity can be addressed with surfactants or organic modi-
fiers, while digestion is improved by combining tryptic 
digestion with chemical approaches such as CNBr-
dependent fragmentation. LC-MS-electrospray (ESI) 
approaches have high throughput and a proven track 
record in membrane protein study [7] and will be used 
in the proposed protocol. 
With Mudpit LC-MS/MS, the peptide mixture is first 
passed through strong cation exchange and reverse 
phase chromatography, separating the peptides ac-
cording to charge and hydrophobicity. As the peptides 
elute, they are ionised by ESI and injected into the 
mass spectrometer, where their mass-to charge ratio 
is determined. Thereafter, peptides are further frac-
tionated and the resulting fractions of each peptide 
analysed in a second mass analyser, creating MS/
MS spectra with peptide sequence information. The 
peptide masses are searched against public data-
bases to identify the proteins they represent [8]. The 
spectral counts, numbers of MS/MS spectra for each 
peptide, are compared between the groups, giving 
relative inter-group peptide levels in a label-free man-
ner [9]. 
1. Clinical sample collection

2. RBC lysis and CD45 depletion

3. Membrane fraction enrichment

4. Protein ID through shotgun LC-MS/MS

5. Validation of findings
Fig. 2. General approach of the protocol. 1. Clinical blood 
samples are collected. RBCs are lysed with a special buffer. The 
samples are incubated with anti-CD45 beads and centrifuged, 
whereafter the CD45 bound WBC fraction is removed. 2. Cells 
are exposed to a biotinylation reagent, which adds biotin tags 
to surface protein amines. Cells are lysed, and biotin-bound 
proteins are captured on avidin-coated resins. 3. Proteins are 
eluted from the resins and subjected to shotgun LC-MS/MS, 
as described above.
 With the expression levels of peptides represented 
as MS/MS spectral counts, the levels will be compared 
between groups. The proteins that are highly overex-
pressed in the cancer group as opposed to healthy 
controls or leukocytes are those that may be con-
sidered for use as CTC markers. The marker panel 
thus created will finally have to be validated. First, the 
surface expression of the markers will be validated 
by immunofluorescence. Those actually present on the 
cell surface will then be validated against another panel 
of blood samples. Validated markers will be used for 
detection of cancer.
The general protocol is as follows:
• Clinical blood samples are subject to RBC lysis.
• Centrifugation with anti-CD45 beads depletes 
WBCs.
• Cell fractions are biotinylated.
• Cell lysis, biotin capture by avidin and elution 
of bound proteins.
• Membrane protein identification through peptide 
identification by LC-MS/MS.
• Protein levels in CTCs, WBCs and controls are 
compared by spectral counts.
• Validation of surface expression of proteins through 
immunofluorescence.
• Validation of markers on new clinical samples.
DISCUSSION
The aim of the proposed protocol is to outline 
a strategy to discover specific and sensitive CTC sur-
face antigens. This would improve detection of CTCs 
by antigen-based methods for early diagnosis of can-
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cer. The described strategy subjects blood samples 
from a range of cancers to membrane enrichment and 
LC-MS/MS, and compares the proteome of the non-
leukocyte membrane fraction of cancer patients to the 
membrane fractions of healthy control non-leukocytes 
and leukocytes from both groups. 
The technical steps in this strategy have already 
been shown to work successfully. Negative enrich-
ment by CD45 depletion yields higher CTC recovery 
rates than positive EpCAM enrichment [5]. Membrane 
protein enrichment through amine biotinylation is not 
limited to capturing glycosylated proteins, as the cell 
surface capture method, and in comparison with col-
loidal silica beads, only proteins present on the outside 
of the membrane will be captured, reducing sample 
complexity. Also, the biotin may be used as a mass tag 
in MS, increasing confidence in that detected peptides 
were present on the cell surface [10]. LC-MS/MS has 
been successfully used in the identification of proteins 
from such membrane fractions [7].
The result of this strategy will be a panel of cell 
surface markers, which will be superior to current CTC 
markers because of the unbiased approach to their 
identification. The markers may be used in devices 
for simultaneous enrichment, detection and enumera-
tion of viable CTCs. Based on the importance of CTCs 
in metastasis, their early intravasation and their corre-
lation with clinical outcomes, better CTC detection will 
be useful in oncological practice. Accurate CTC mark-
ers will allow early diagnosis and in-depth characteri-
sation of cancer, as well as treatment personalisation 
based on CTC phenotype and response monitoring 
through counting CTCs after treatment.
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